trending Market Intelligence /marketintelligence/en/news-insights/trending/3Opc2U-irQwx5TreESOArA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Jury favors Johnson & Johnson, Bayer in 2nd trial over blood-thinning drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Jury favors Johnson & Johnson, Bayer in 2nd trial over blood-thinning drug

A New Orleans jury ruled that Johnson & Johnson and Bayer AG are not at fault for the death of a woman who had taken blood-thinning drug Xarelto, Bloomberg News reported.

The family of 67-year-old Sharyn Orr blamed her death on the drug, which was jointly developed by the two companies. Orr began taking Xarelto in February 2014 and died in May 2015, following a massive brain hemorrhage.

The decision is the second straight win for the companies, following an earlier decision in May. There are still more than 18,000 patient lawsuits over the drug. U.S. Food and Drug Administration reports indicate that Xarelto has been linked to at least 370 deaths, according to Bloomberg News.

The next trial is scheduled for Aug. 7 in federal court in Jackson, Miss.